What is it about?
To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.
Photo by Fernando @cferdo on Unsplash
Why is it important?
Selective serotonin reuptake inhibitors (SSRIs) came onto the market almost 20 years ago and can result sexual dysfunction (SD) in a significant proportion of men who are taking these medications. The reported frequency of SSRI-associated SD varies significantly, from small percentages to >80%. The exact frequency of SSRI-induced SD is not known. One reason is that the prevalence of male SD in the general population is high which makes it difficult to establish a baseline normal sexual function. Approaches to obtaining data on SSRI-emergent SD might be influenced by marketing strategies, and the condition has been under-reported. However, according to existing reports, at least a third of patients taking SSRIs will complain of treatment-emergent SD.
Read the Original
This page is a summary of: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study, BJU International, August 2010, Wiley, DOI: 10.1111/j.1464-410x.2009.09154.x.
You can read the full text:
The following have contributed to this page